AvantGuard has been awarded a $325K NIH Phase I Grant for non-coating antimicrobial, anti-host deposition, anti-inflammatory urinary...

NEW YORK, May 11, 2023 /PRNewswire/ -- AvantGuard, a fast-growing company in the antimicrobial industry, announced today the successful...

AvantGuard, Inc. is pleased to announce a $1.7 million Phase II SBIR award from the National Institutes of Health (NIH) to continue...

ITHACA, N.Y., March 23, 2023 /PRNewswire/ -- AvantGuard, announced today the unveiling of its new brand identity as a transformative...